Insilico announces Deep Longevity, a spin-out that will collaborate with Human Longevity Inc. to deploy an extensive range of AI-powered aging clocks.
Insilico Medicine has announced a new subsidiary spin-out that has developed new AI-tech to calculate biological age. Deep Longevity will partner with Human Longevity Inc (HLI) to launch the first scalable AI system for aging-related biomarker development to deploy the technology worldwide.
Longevity.Technology: The timing is well-judged; biomarkers of aging are big news, because how can we evaluate Longevity therapies if we can’t measure success? Measuring the differences between biological and chronological age, seeing how that varies from organ-to-organ, how aging is affected by genetic factors, lifestyle choices and therapies – these all need state-of-the-art aging clocks, so we are really excited by this announcement, which combines Insilico’s expertise on deep learning for aging research with HLI’s proactive healthcare and health intelligence.
Deep Longevity is a Longevity-focused AI spin-off that will develop and provide the customised predictors of human biological age to the network of Human Longevity Inc (HLI) concierge Longevity clinicians. Specialising in the development of deep biomarkers of aging using clinical blood tests, transcriptomic, proteomic, epigenetic, microbiome, behavioural, wearable, imaging and multiple other data types, Deep Longevity will provide a broad range of deep aging clocks to some of the world’s most advanced Longevity clinics and physicians and is developing a range of simple consumer applications to track the rate of aging at the individual level.
The company has released a demo of a typical personalised report. It links to young.ai which requires a login and appears to still be in beta.
The company is developing a comprehensive decision support system for physicians to enable the development of personalised Longevity protocols using the latest advances in Longevity biotech and has exclusively licensed a portfolio of granted and pending patents on aging clocks developed using the latest advances in AI. Deep Longevity’s team of scientists and AI researchers invented the industry’s first-ever aging clocks using deep neural networks and identified aging-related biomarkers for diseases like diabetes, sarcopenia and NASH (non-alcoholic steatohepatitis).
HLI is a a genomics-based, health intelligence company that seeks to empower proactive healthcare and enable a life better lived. HLI’s business focus includes the Health Nucleus, a genomic-powered, precision medicine centre that uses whole-genome sequencing analysis, advanced imaging and blood analytics, to deliver a complete picture of individual health.
We explored HLI’s model in our exclusive video interview with HLI’s Wei-Wu He, executive chairman of Human Longevity. They have big plans.
The new ventures’ Series A has a stellar roster of investors:
Led by ETP Ventures and Human Longevity and Performance Impact Venture Fund (“HLPIVF”), the investment round includes participation from BOLD Capital Partners, Longevity Vision Fund, Oculus co-founder and former chief software architect Michael Antonov through Formic Ventures, and LongeVC. Deep Longevity also claims celebrity investors in AI and prominent US biotech investors among its undisclosed investors.
“… Deep Longevity will translate these discoveries into the new industry of longevity management and medicine providing longevity as a service …”
“Over the past few years, our team made several discoveries in the field of deep learning for longevity research in both biomarkers of aging and geroprotector discovery,” said Alex Zhavoronkov, PhD, founder and CEO of Deep Longevity. “Deep Longevity will translate these discoveries into the new industry of longevity management and medicine providing longevity as a service. To enable early access to these technologies we partnered with the most prominent concierge longevity practice, Human Longevity. We are happy to announce this round of funding provided by the top experts in longevity, biotechnology, and artificial intelligence. We will help power their longevity ecosystem with a standardized set of aging and longevity biomarkers.”
“The longevity industry is rapidly evolving and is likely to become the largest industry on the planet …”
“The longevity industry is rapidly evolving and is likely to become the largest industry on the planet,” said Wei-Wu He, PhD, MBA, executive chairman of Human Longevity. “At Human Longevity we are dedicated to building the innovative longevity biotechnology ecosystem enabling technologies that can help our customers and our network of longevity physicians. One of the main breakthroughs of the past decade is the invention of the so-called aging clocks, biomarkers of aging that allow us to measure the rate of aging and evaluate the effectiveness of the various interventions. ETP Ventures and HLPIVF are investing in Deep Longevity because of their proven technology leadership in the development of AI-based aging clocks using many data types. These clocks will be available in the near future to our scientists, physicians, and our
Photo by Tomas Anunziata from Pexels